Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00452179 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of APD125 in Patient With Insomnia
A Phase 2 study of Insomnia, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
- 1
- Study location
NCT00452179 is a Phase 2 study of Insomnia that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 173 participants, roughly in line with the 169-participant average among 151 other Insomnia trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00452179, a Phase 2 study of Insomnia, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects of APD125 in patients with sleep maintenance insomnia.
Conditions Studied
Interventions
- DRUG APD125
Study Locations (1)
California
- - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00452179
The ClinicalTrials.gov registry entry for NCT00452179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 169-participant average among 151 other Insomnia trials with a reported enrollment target. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 1 intervention - of which APD125 is the first listed.
NCT00452179 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00452179 about?
NCT00452179 is a clinical study titled "Safety and Efficacy Study of APD125 in Patient With Insomnia". The purpose of this study is to determine the effects of APD125 in patients with sleep maintenance insomnia.
What is the current status of trial NCT00452179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2007-02. Estimated completion is 2007-06.
What conditions does trial NCT00452179 study?
This clinical trial studies the following conditions: Insomnia.
What interventions are being tested in trial NCT00452179?
The interventions under investigation include: APD125 (DRUG).
Who is sponsoring clinical trial NCT00452179?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00452179 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Pimavanserin for Insomnia in Veterans With PTSD
RECRUITING · Phase 2
-
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
RECRUITING · Phase 2
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Suvorexant for Treatment of AUD and PTSD
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.